Optically Active 2-Methylpiperazine Crystallization via Azeotropic Solvent Replacement
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing optically active 2-methylpiperazine result in a product with high melting point, making it difficult to handle, and involve lengthy processes with impurity complications, lacking an industrially viable method for producing high-purity, easily handleable crystals.
Innovation Solution
A method involving solvent azeotropic distillation with water-insoluble organic solvents like toluene or cyclopentyl methyl ether to remove water, concentrate the solution, and crystallize optically active 2-methylpiperazine, using seed crystals for efficient crystallization, which simplifies the process and reduces impurities.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If the optically active 2-methylpiperazine is isolated by distillation, then the optically active 2-methylpiperazine can be obtained, but the product has a high melting point of from 91 to 93°C and solidifies at room temperature, making it difficult to handle
Solution Approach 1:
The invention changes the physical state parameter of the product by controlling crystallization conditions to obtain a solvate form with different melting properties. By adjusting the solvent system and crystallization parameters, the product is transformed from a high-melting solid (91-93°C) to a solvate crystalline form with improved handleability while maintaining optical purity.
Solution Approach 2:
The invention creates a composite crystalline structure by forming a solvate between optically active 2-methylpiperazine and a specific solvent (cyclopentyl methyl ether or toluene). This solvate composite has different physical properties including lower melting point and improved handleability compared to the pure compound, while maintaining the optical activity.
2Ease of operation
If the mineral acid salt is reacted with an alkali metal alkoxide in a lower alcohol to isolate the optically active 2-methylpiperazine, then the product can be obtained as crystals, but an excess amount of alkali metal alkoxide and inorganic salt are dissolved and mixed into the solution, requiring additional purification steps
Solution Approach 1:
The invention extracts and removes potential impurities (alkali metal alkoxide and inorganic salt) from the system by using a specific solvent system where these substances remain insoluble or can be easily separated. The use of cyclopentyl methyl ether or toluene as the solvent allows direct crystallization of the pure solvate form without co-dissolving the impurities, thereby eliminating the need for additional purification steps.
Solution Approach 2:
The invention introduces a specific solvent (cyclopentyl methyl ether or toluene) as an intermediary medium that facilitates the crystallization of optically active 2-methylpiperazine in a pure form. This intermediary solvent mediates between the starting materials and the final product, enabling direct formation of the desired crystalline solvate while leaving impurities behind in the mother liquor.
3Manufacturing precision
If the optically active 2-methylpiperazine is produced by forming diastereoisomeric salts with optically active tartaric acid and separating the salts, then the optically active 2-methylpiperazine can be obtained, but the production process becomes lengthy and complex
Solution Approach 1:
Instead of following the conventional route of forming diastereoisomeric salts, separating them, and then liberating the amine (which is lengthy), the invention inverts the approach by directly crystallizing the optically active 2-methylpiperazine as a solvate from the reaction mixture. This reversal of the traditional sequence eliminates the salt formation and decomposition steps, significantly reducing production time while maintaining optical purity.
Solution Approach 2:
The invention skips the intermediate steps of diastereoisomeric salt formation and decomposition by directly obtaining the optically active 2-methylpiperazine through selective crystallization. This shortcut approach rushes through the traditional multi-step process by utilizing the solubility differences and crystallization behavior of the solvate form, thereby eliminating unnecessary time-consuming operations.
4Ease of operation
If a method is used that includes a step of forming the mineral acid salt of the optically active 2-methylpiperazine, then the optically active 2-methylpiperazine can be isolated as crystals, but the production process becomes longer
Solution Approach 1:
The invention merges the crystallization step with the product formation step by directly obtaining the optically active 2-methylpiperazine as a solvate crystalline form from the reaction mixture. This combines what would traditionally be separate steps (product formation and crystallization) into a single operation, eliminating the need for intermediate salt formation and subsequent crystallization, thereby reducing production time while maintaining good handleability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method reduces production costs, improves handleability, and achieves high-purity optically active 2-methylpiperazine crystals, enhancing its usability as a pharmaceutical raw material with a shorter production process.
Implementation Method 1
adding a solvent azeotropic with water selected from toluene and cyclopentyl methyl ether to a solution of the optically active 2-methylpiperazine to carry out solvent replacement, removing water by azeotropic distillation
Implementation Method 2
concentrating the solution of the optically active 2-methylpiperazine from which water has been removed and then obtaining crystals of the optically active 2-methylpiperazine by crystallization
Data Source
Figure 1
Figure 2
AI summary
The present invention provides a method for producing an optically active 2-methylpiperazine including: adding a solvent to a solution of the optically active 2-methylpiperazine to carry out solvent replacement, and then being crystallized to obtain crystals of the optically active 2-methylpiperazine. The method for producing an optically active 2-methylpiperazine according to the present invention allows the optically active 2-methylpiperazine to be purified during the crystallization process, and thus it is possible to obtain an optically active 2-methylpiperazine having a high quality.